Deutsche Bank announced on Friday that it had lowered its price target for Ipsen from €115 to €113, while renewing its 'hold' recommendation on the stock.

In a research note, the research firm points to an unsurprising fourth-quarter publication, just as the French biopharmaceutical group's fiscal year 2024 is shaping up to be lackluster.

From its point of view, investors' attention remains focused on good commercial execution and the impact of generic competition on its flagship product, Somatuline, which could make market earnings estimates volatile.

According to Deutsche Bank, only a transforming acquisition would be likely to revive investor interest in the case and boost confidence in the Group's future profitability.

Pending a high-profile transaction in the field, and in view of the uncertainty surrounding the erosion of the Somatuline franchise, Deutsche explains that it prefers to revise its forecasts downwards.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.